Skip to Content

Dysport Approval History

Dysport (abobotulinumtoxinA) is an acetylcholine release inhibitor and neuromuscular blocking agent for the treatment of cervical dystonia, for the temporary improvement in the appearance of moderate to severe glabellar lines, upper limb spasticity in adults, and lower limb spasticity in pediatric patients.

Development History and FDA Approval Process for Dysport

Aug  1, 2016Approval Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older
Jul 17, 2015Approval Ipsen Announces FDA Approval of Dysport (abobotulinumtoxinA) for Upper Limb Spasticity
Apr 30, 2009Approval FDA Approves Dysport for Therapeutic and Aesthetic Uses
Dec 29, 2008FDA Issues Complete Response Letter to Ipsen for Dysport Biologics License Application
May 19, 2008Ipsen and Medicis Announce Acceptance of Reloxin BLA in Aestheticsby FDA
Mar 17, 2008Ipsen and Medicis announce submission of Reloxin BLA inaesthetics to the FDA
Jan 31, 2008Ipsen: FDA Accepts for Filing a Biologics License Application (BLA) for Dysport in Cervical Dystonia
Dec  6, 2007Ipsen and Medicis Announce Submission of Reloxin in Aesthetics tothe FDA
Dec  6, 2007Ipsen Submits a Biologics License Application in Cervical Dystonia to the FDA for Dysport

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.